Does prostaglandin D2 hold the cure to male pattern baldness?

Ashley Nieves, Luis Garza

Research output: Contribution to journalArticle

Abstract

Lipids in the skin are the most diverse in the entire human body. Their bioactivity in health and disease is underexplored. Prostaglandin D2 has recently been identified as a factor which is elevated in the bald scalp of men with androgenetic alopecia (AGA) and has the capacity to decrease hair lengthening. An enzyme which synthesizes it, prostaglandin D2 synthase (PTGDS or lipocalin-PGDS), is hormone responsive in multiple other organs. PGD2 has two known receptors, GPR44 and PTGDR. GPR44 was found to be necessary for the decrease in hair growth by PGD2. This creates an exciting opportunity to perhaps create novel treatments for AGA, which inhibit the activity of PTGDS, PGD2 or GPR44. This review discusses the current knowledge surrounding PGD2, and future steps needed to translate these findings into novel therapies for patients with AGA.

Original languageEnglish (US)
Pages (from-to)224-227
Number of pages4
JournalExperimental Dermatology
Volume23
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Prostaglandin D2
Alopecia
prostaglandin R2 D-isomerase
Hair
Bioactivity
Scalp
Human Body
Skin
Health
Hormones
Lipids
Enzymes
Therapeutics
Growth

Keywords

  • Aging
  • Alopecia
  • Arachidonic acid
  • Baldness
  • Hair
  • Lipids
  • Prostaglandins

ASJC Scopus subject areas

  • Dermatology
  • Molecular Biology
  • Biochemistry
  • Medicine(all)

Cite this

Does prostaglandin D2 hold the cure to male pattern baldness? / Nieves, Ashley; Garza, Luis.

In: Experimental Dermatology, Vol. 23, No. 4, 2014, p. 224-227.

Research output: Contribution to journalArticle

@article{59427758e1b84dd0b81bd16136cb6d14,
title = "Does prostaglandin D2 hold the cure to male pattern baldness?",
abstract = "Lipids in the skin are the most diverse in the entire human body. Their bioactivity in health and disease is underexplored. Prostaglandin D2 has recently been identified as a factor which is elevated in the bald scalp of men with androgenetic alopecia (AGA) and has the capacity to decrease hair lengthening. An enzyme which synthesizes it, prostaglandin D2 synthase (PTGDS or lipocalin-PGDS), is hormone responsive in multiple other organs. PGD2 has two known receptors, GPR44 and PTGDR. GPR44 was found to be necessary for the decrease in hair growth by PGD2. This creates an exciting opportunity to perhaps create novel treatments for AGA, which inhibit the activity of PTGDS, PGD2 or GPR44. This review discusses the current knowledge surrounding PGD2, and future steps needed to translate these findings into novel therapies for patients with AGA.",
keywords = "Aging, Alopecia, Arachidonic acid, Baldness, Hair, Lipids, Prostaglandins",
author = "Ashley Nieves and Luis Garza",
year = "2014",
doi = "10.1111/exd.12348",
language = "English (US)",
volume = "23",
pages = "224--227",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Does prostaglandin D2 hold the cure to male pattern baldness?

AU - Nieves, Ashley

AU - Garza, Luis

PY - 2014

Y1 - 2014

N2 - Lipids in the skin are the most diverse in the entire human body. Their bioactivity in health and disease is underexplored. Prostaglandin D2 has recently been identified as a factor which is elevated in the bald scalp of men with androgenetic alopecia (AGA) and has the capacity to decrease hair lengthening. An enzyme which synthesizes it, prostaglandin D2 synthase (PTGDS or lipocalin-PGDS), is hormone responsive in multiple other organs. PGD2 has two known receptors, GPR44 and PTGDR. GPR44 was found to be necessary for the decrease in hair growth by PGD2. This creates an exciting opportunity to perhaps create novel treatments for AGA, which inhibit the activity of PTGDS, PGD2 or GPR44. This review discusses the current knowledge surrounding PGD2, and future steps needed to translate these findings into novel therapies for patients with AGA.

AB - Lipids in the skin are the most diverse in the entire human body. Their bioactivity in health and disease is underexplored. Prostaglandin D2 has recently been identified as a factor which is elevated in the bald scalp of men with androgenetic alopecia (AGA) and has the capacity to decrease hair lengthening. An enzyme which synthesizes it, prostaglandin D2 synthase (PTGDS or lipocalin-PGDS), is hormone responsive in multiple other organs. PGD2 has two known receptors, GPR44 and PTGDR. GPR44 was found to be necessary for the decrease in hair growth by PGD2. This creates an exciting opportunity to perhaps create novel treatments for AGA, which inhibit the activity of PTGDS, PGD2 or GPR44. This review discusses the current knowledge surrounding PGD2, and future steps needed to translate these findings into novel therapies for patients with AGA.

KW - Aging

KW - Alopecia

KW - Arachidonic acid

KW - Baldness

KW - Hair

KW - Lipids

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=84896995060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896995060&partnerID=8YFLogxK

U2 - 10.1111/exd.12348

DO - 10.1111/exd.12348

M3 - Article

C2 - 24521203

AN - SCOPUS:84896995060

VL - 23

SP - 224

EP - 227

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

IS - 4

ER -